Preventing neural tube defects: The importance of periconceptional folic acid supplements

Obstetrics and Gynecology

Volumn 91, Issue 6, 1998, Pages 1027-1034

  Locksmith, Gregory J ^a   Duff, Patrick ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; FOLIC ACID; VALPROIC ACID;

CONVULSION; DIET SUPPLEMENTATION; DOSE CALCULATION; DRUG BIOAVAILABILITY; FEMALE; HUMAN; INCIDENCE; NEURAL TUBE DEFECT; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; VITAMIN INTAKE;

FEMALE; FOLIC ACID; HUMANS; INCIDENCE; INFANT, NEWBORN; NEURAL TUBE DEFECTS; NUTRITION POLICY; PREGNANCY; VITAMINS;

EID: 0031861641     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0029-7844(98)00060-X     Document Type: Review

References (55)

1. Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects. MMWR Morb Mortal Wkly Rep 1992;41(RR-14):1-7.
2. Laurence K.M., James N., Miller M.H., Tennant G.B., Campbell H. Double-blind randomized controlled trial of folate treatment before conception to prevent recurrence of neural tube defects. BMJ. 282:1981;1509-1511.
3. Prevention of neural tube defects: Results of the Medical Research Council Vitamin Study. MRC Vitamin Study Research Group. Lancet. 338:1991;131-137.
4. Czeizel A.E., Dudas I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med. 327:1992;1832-1835.
5. Kirke P.N., Daly L.E., Elwood J.H. A randomised trial of low dose folic acid to prevent neural tube defects. Arch Dis Child. 67:1992;1442-1446.
6. Smithells R.W., Nevin N.C., Seller M.J., Sheppard S., Harris R., Read A.P. Further experience of vitamin supplementation for the prevention of neural tube defect recurrences. Lancet. 1:1983;1027-1031.
7. Vergel R.G., Sanchez L.R., Heredero B.L., Rodriguez P.L., Martinez A.J. Primary prevention of neural tube defects with folic acid supplementation Cuban experience . Prenat Diagn. 10:1990;149-152.
8. Milunsky A., Jick H., Jick S.S., Bruell C.L., MacLaughlin D.S., Rothman K.J., et al. Multivitamin/folic acid supplementation in early pregnancy reduces the prevalence of neural tube defects. JAMA. 262:1989;2847-2852.
9. Mulinare J., Cordero J.F., Erickson J.D., Berry R.J. Periconceptional use of multi-vitamins and the occurrence of neural tube defects. JAMA. 260:1988;3141-3145.
10. Bower C., Stanley F.J. Dietary folate as a risk factor for neural tube defects Evidence from a case-control study in Western Australia . Med J Aust. 150:1989;613-618.
11. Werler M.M., Shapiro S., Mitchell A.A. Periconceptional folic acid exposure and risk of occurrent neural tube defects. JAMA. 269:1993;1257-1261.
12. Shaw G.M., Shaffer D., Velie E.M., Morland K., Harris J.A. Periconceptional vitamin use, dietary folate, and the occurrence of neural tube defects. Epidemiology. 6:1995;219-226.
13. Erbe R.W., Wang J.C. Folate metabolism in humans. Am J Med Genet. 17:1984;277-287.
14. Herbert V. Recommended daily intakes (RDI) of folate in humans. Am J Clin Nutr. 45:1987;661-670.
15. 12 are independent risk factors for neural tube defects. Q J Med. 86:1993;703-708.
16. Gunter E.W., Bowman B.A., Caudill S.P., Twite D.B., Adams M.J., Sampson E.J. Results of an international round robin for serum and whole-blood folate. Clin Chem. 42:1996;1689-1694.
17. Van Allen M.I., Kalousek D.K., Chernoff G.F., Juriloff D., Harris M., McGillivray B.C. Evidence for multi-site closure of the neural tube in humans. Am J Med Genet. 47:1993;723-743.
18. Congenital malformations worldwide A report from the International Clearinghouse for Birth Defects Monitoring Systems . 1991;41-51 Elsevier, Amsterdam.
19. Elwood J.M., Little J., Elwood J.H. Epidemiology and control of neural tube defects. 1992;Oxford University Press, Oxford.
20. Smithells R.W., Sheppard S., Schorah C.J. Vitamin deficiencies and neural tube defects. Arch Dis Child. 51:1976;944-949.
21. Laurence K.M., James N.E., Miller M.H., Tennant G.B., Campbell H. Increased risk of recurrence in pregnancies complicated by fetal neural tube defects in mothers receiving poor diets, and possible benefit of dietary counseling. BMJ. 281:1980;1592-1594.
22. Mills J.L., Rhoads G.G., Simpson J.L., Cunningham G.C., Conley M.R., Lassman M.R., et al. The absence of a relation between the periconceptional use of vitamins and neural tube defects. N Engl J Med. 321:1989;430-435.
23. Yates J.R.W., Ferguson-Smith M.A., Shenkin A., Guzman-Rodriguez R., White M., Clark B.J. Is disordered folate metabolism the basis for the genetic predisposition to neural tube defects? Clin Genet. 31:1987;279-287.
24. 12 in relation to neural tube defects. Br J Obstet Gynaecol. 103:1996;319-324.
25. Daly L.E., Kirke P.N., Molloy A., Weir D.G., Scott J.M. Folate levels and neural tube defects Implications for prevention . JAMA. 274:1995;1698-1702.
26. Brown J.E., Jacobs D.R. Jr, Hartman T.J., Barosso G.M., Stang J.S., Gross M.D., et al. Predictors of red cell folate level in women attempting pregnancy. JAMA. 277:1997;548-552.
27. Tucker K.L., Mahnken B., Wilson P.W.F., Jacques P., Selhub J. Folic acid fortification of the food supply Potential benefits and risks for the elderly population . JAMA. 276:1996;1879-1885.
28. Mills J.L., McPartin J.M., Kirke P.N., Lee Y.J., Conley M.R., Weir D.G., et al. Homocysteine metabolism in pregnancies complicated by neural tube defects. Lancet. 345:1995;149-151.
29. Steegers-Theunissen R.P.M., Boers G.H.J., Trijbels F.J.M., Finkelstein J.D., Blom H.J., Thomas C.M.G., et al. Maternal hyperhomocysteinemia A risk factor for neural tube defects? Metabolism. 43:1994;1475-1480.
30. Boers G.H.J., Smals A.G.H., Drayer J.I.M., Trijbels F.J.M., Leermakers A.I., Kloppenborg P.W. Pyridoxine treatment does not prevent homocysteinemia after methionine loading in adult homocystinuria patients. Metabolism. 32:1983;390-397.
31. Brattstrom L., Isrealsson B., Norrving B., Bergqvist D., Thorne J., Hultberg B., et al. Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive disease - effects of pyridoxine and folic acid treatment. Atherosclerosis. 81:1990;51-60.
32. Olszewski A.J., Szostak W.B., Bialkowska M., Rudnicki S., McKully K.S. Reduction of plasma lipid and homocysteine levels by pyridoxine, folate, cobalamin, choline, riboflavin, and troxerutin in atherosclerosis. Atherosclerosis. 75:1989;1-6.
33. Brattstrom L.E., Israelsson B., Jeppsson J.O., Hultberg B.L. Folic acid An innocuous means to reduce plasma homocysteine . Scand J Clin Lab Invest. 48:1988;215-221.
34. 12 alters the frequency of neural tube defects in Axd mutant mice. J Nutr. 123:1993;27-34.
35. Coelho C.N.D., Klein N.W. Methionine and neural tube closure in cultured rat embryos Morphological and biochemical analyses . Teratology. 42:1990;437-451.
36. Rosenquist T.H., Ratashak S.A., Selhub J. Homocysteine induces congenital defects of the heart and neural tube Effect of folic acid . Proc Natl Acad Sci USA. 93:1996;15227-15232.
37. Kirke P.N., Mills J.L., Whitehead A.S., Molloy A., Scott J.M. Methylenetetrahydrofolate reductase mutation and neural tube defects. Lancet. 348:1996;1037-1038.
38. Kang S.S., Wong P.W.K., Susmano A., Sora J., Norusis M., Ruggie N. Thermolabile methylenetetrahydrofolate reductase An inherited risk factor for coronary artery disease . Am J Hum Genet. 48:1991;536-545.
39. Molloy A.M., Daly S., Mills J.L., Kirke P.N., Whitehead A.S., Ramsbottom D., et al. Thermolabile variant of 5,10-methylenetetrahydrofolate reductase associated with low red-cell folates Implications for folate intake recommendations . Lancet. 349:1997;1591-1593.
40. Kang S.S., Zhou J., Wong P.W.K., Kowalisyn J., Strokosch G. Intermediate hyperhomocysteinemia A thermolabile defect of methylenetetrahydrofolate reductase . Am J Hum Genet. 43:1988;414-421.
41. Whitehead A.S., Gallagher P., Mills J.L., Kirke P.N., Burke H., Molloy A.M., et al. A genetic defect in 5,10-methylenetetrahydrofolate reductase in neural tube defects. Q J Med. 88:1995;763-766.
42. van der Put N.M.J., Steegers-Theunissen R.P.M., Frosst P., Trijbels F.J.M., Eskes T.K.A.B., van den Heuvel L.P., et al. Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet. 346:1995;1070-1071.
43. Ou C.Y., Stevenson R.E., Brown V.K., Schwartz C.E., Allen W.P., Khoury M.J., et al. 5,10 methylenetetrahydrofolate reductase genetic polymorphism as a risk factor for neural tube defects. Am J Med Genet. 63:1996;610-614.
44. Hook E.B., Czeizel A.E. Can terathanasia explain the protective effect of folic acid supplementation of birth defects? Lancet. 350:1997;513-515.
45. Subar A.F., Block G., James L.D. Folate intake and food sources in the U.S. population. Am J Clin Nutr. 50:1989;508-516.
46. U.S. Preventive Services Task Force. Guide to clinical preventive services: Report of the U.S. Preventive Services Task Force. 2nd ed. Baltimore: Williams & Wilkins, 1996.
47. US Public Health Service. Use of folic acid for prevention of spina bifida and other neural tube defects - 1983-1991. MMWR Morb Mortal Wkly Rep 1991;40:513-6.
48. American College of Obstetricians and Gynecologists. Folic acid for the prevention of neural tube defects. ACOG committee opinion no. 120. Washington, DC: American College of Obstetricians and Gynecologists, 1993.
49. US Public Health Service. Knowledge and use of folic acid by women of childbearing age - United States, 1997. MMWR Morb Mortal Wkly Rep 1997;46:721-3.
50. Hawkes J.G., Villota R. Folates in foods Reactivity, stability during processing, and nutritional implications . Crit Rev Food Sci Nutr. 28:1989;439-538.
51. US Dept of Health and Human Services, Food and Drug Administration. Food standards: Amendment of the standards of identity for enriched grain products to require addition of folic acid. Federal Register 1993;58:53306-12.
52. Holmes-Seidle M., Dennis J., Lindenbaum R.H., Galliard A. Long-term effects of periconceptional multivitamin supplements for prevention of neural tube defects A seven to ten year follow up . Arch Dis Child. 67:1992;1436-1441.
53. Schwartz S.O., Kaplan S.R., Armstrong B.E. The long-term evaluation of folic acid treatment of pernicious anemia. J Lab Clin Med. 35:1950;894-898.
54. Healton E.B., Savage D.G., Brust J.C., Garrett T.J., Lindenbaum J. Neurologic aspects of cobalamin deficiency. Medicine. 70:1991;229-245.
55. 12 deficiency is the primary cause of megaloblastic anaemia in Zimbabwe. Br J Haematol. 86:1994;844-850.